Portola Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 15 of 15 Posts
Wall Street's Top Stories For Monday, Dec 31
Article By: The Fly Monday, December 31, 2018 5:12 PM EDT
Though December has been a bad month for the market, stocks opened in positive territory on the prospects of progress in the trade negotiations between the U.S. and China. Plus company news updates on Amazon, Disney, Verizon, and more.
In this article: CWH, DIS, VZ, AMZN, HRTX, PTLA, APHA
Read
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich Friday, January 26, 2018 6:44 PM EDT
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
Citi Still Expects FDA Approval For Portola Despite 90 Day Delay
Article By: The Fly Thursday, December 28, 2017 7:39 AM EDT
After speaking to management, Citi analyst Yigal Nochomovitz expects Portola Pharmaceuticals' AndexXa to be approved on or before the new FDA action date of May 4, 2018.
In this article: PTLA
Read
Portola: Potential Launch Date For Bevyxxa And Price Announcement
Article By: SmithOnStocks Wednesday, September 6, 2017 10:55 AM EDT
Portola ended 2Q, 2017 with $270 million of cash which management states can fund operations into 1Q, 2018. The Company is going to require a very significant amount of cash to fund the launch of Bevyxxa and AndexXa.
In this article: PTLA
Read
Under The Radar: 3 “Strong Buy” Stocks To Know Now
Article By: TipRanks Sunday, August 13, 2017 9:08 AM EDT
The inclusion of one of the world’s largest steel producers, United States Steel may come as a surprise. At the end of April, US Steel suffered its biggest stock collapse since going public 26 years ago.
In this article: PTLA, X, TTD
Read
Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy
Article By: SmithOnStocks Tuesday, August 8, 2017 1:54 PM EDT
Portola issued a press release on August 3, 2017, that reported it had just resubmitted the BLA for AndexXa, which is in line with prior management guidance.
In this article: PTLA
Read
5 Top-Rated Biotech Stocks With Big Upside Potential
Article By: TipRanks Wednesday, June 28, 2017 6:58 AM EDT
Given the risk inherent in this sector it is important to pick stocks wisely- and choosing stocks recommended by top analysts is one way of pinpointing top biotech stocks.
In this article: MDWD, BDSI, PTLA, ALXN, CUTR
Read
Which Stocks Are Five-Star Insiders Buying And Selling Right Now?
Article By: TipRanks Sunday, June 4, 2017 5:30 PM EDT
If insiders are buying shares in a stock with their own money it can be a good indication of a compelling investment opportunity. Selling can indicate the reverse.
In this article: DKS, LHCG, PTLA, WLTW
Read
3 Undervalued Stocks With Strong Upcoming Catalysts
Article By: Bret Jensen Saturday, July 16, 2016 12:49 PM EDT
If all goes well for these 3 stocks, in the next 6 months they could be worth over double the prices they currently trade for. Each stock has important, business-defining events that would make their businesses significantly more valuable.
In this article: NVAX, EGLT, PTLA Also: PFE, EXEL
Read
E Portola Pharmaceuticals Inc. Is A Stock To Watch With Caution Ahead Of PDUFA
Article By: Samuel Rae Thursday, July 7, 2016 1:14 PM EDT
Portola Pharmaceuticals Inc (PTLA) could recover its year to date losses come its August PDUFA. Here's both sides of the story.
In this article: PTLA
Read
4 Takeover Stocks To Buy This Summer
Article By: Bret Jensen Sunday, June 5, 2016 10:39 AM EDT
Biotech has gone a real tear over the past three weeks after making several “false starts” over the past several months as it emerges from an immense bear market that began late in July of last year. This move feels more real than previous bounces.
In this article: ACAD, ARDX, BIIB, PTLA, RLYP Also: ANAC, XNPT, ABBV, CPXX, AGN, PFE, MDVN, MRK, SNY
Read
Is PTLA Sell-Off An Overreaction?
Article By: KKD Healthcare Analytics Monday, March 28, 2016 11:18 AM EDT
Portola's shares dropped 30% on the last trading day before the holiday weekend, and another 6% today.
In this article: PTLA
Read
E Portola Pharmaceuticals, Inc. Falls 30% After Announcing Phase 3 Trial Failure
Article By: Terry Chrisomalis Thursday, March 24, 2016 7:00 PM EDT
Today, shares of Portola Pharmaceuticals, Inc. (PTLA) fell by 30% after it announced that its oral anticoagulant drug betrixaban failed to produce significant results in a phase 3 study.
In this article: PTLA Also: SNY
Read
Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital
Article By: The Life Sciences Report Thursday, March 3, 2016 7:53 AM EDT
Eden Rahim of Toronto-based Next Edge Capital describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot.
In this article: LLY, MBXBF, IBB, BIIB, REPCF, XLV, BCLI, AXON, CPHR, NTRP, SGYP, ACAD, MDVN, PTLA, ITCI, ALPMF
Read
EC Five Pharma Picks For 2016: Credit Suisse
Article By: ValueWalk Wednesday, December 23, 2015 3:34 AM EDT
Analysts at Credit Suisse believe that 2016 is set to be yet another volatile year for the sector, especially small and mid-cap names. However, they believe that seven pharmaceutical names have what it takes to outperform.
In this article: ALKS, ESPR, PTLA, MYOK, ADMS
Read
1 to 15 of 15 Posts